Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China
(WorldNews Norway)

Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China · IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 · If exercised, the license has a potential value of up to USD 100 million in development and commercial milestones, in addition to double-digit royalties · The parties will negotiate a full License Agreement based on pre-agreed terms and principles in the Option Agreement Oslo, Norway 8 January 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno -oncology company developing oncolytic viruses and cancer vaccines...